Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 42kWORD 10k
25 February 2022
Question for written answer  E-000805/2022
to the Commission
Rule 138
João Pimenta Lopes (The Left)
 Answer in writing 
 Subject: Distribution of vaccines to third countries under the COVAX programme

In her State of the Union address, the President of the European Commission claimed that the EU distributed 700 million vaccines in 2021, to more than 130 countries, and promised to distribute a further 200 million by the middle of this year. At the same time, up to EUR 3 billion would be made available for the COVAX programme(1). However, according to UN sources, by September 2021, only 42 million of the 700 million doses pledged by the end of that year had made it to Africa.(2)

Meanwhile, the EU continues to block the proposed patent waiver tabled by South Africa and India at the World Trade Organization, a move that not only reflects a lack of real solidarity but also hampers a truly global vaccination rollout to fight the negative effects of COVID-19.

In view of the above:

1. How many vaccines (broken down by region and country) has the EU distributed to third countries through COVAX?

2. What conditions or guarantees are required of beneficiary countries?

3. Given the spread of the disease, is the Commission considering proposing a patent waiver for the COVID-19 vaccines?

Original language of question: PT
Last updated: 7 March 2022Legal notice - Privacy policy